Q-omics provides the consensus-scored LYZL2 profile across patient tissues and cancer cell-line models. LYZL2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LYZL2 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, LYZL2 RNA expression shows 6,577 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, BRCA, and STAD as cancer lineages where LYZL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYZL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYZL2 survival associations across molecular data types. LYZL2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYZL2 RNA expression–survival associations across cancer types. High LYZL2 expression shows unfavorable associations in UCS, LGG, THYM, KIRC and CHOL, but favorable associations in HNSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LYZL2 RNA expression.
This table summarizes LYZL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LYZL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYZL2 shows higher tumor expression in BRCA, LUAD, LIHC, PRAD and COAD. The BRCA box plot shows higher LYZL2 RNA expression in tumor versus normal tissue (log2 FC = +0.207, t-test p < 0.001).
This table shows molecular features associated with LYZL2 in patient tissues and cancer cell lines. In patient samples, LYZL2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LYZL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
